A venture capital firm based in the USA can invest anywhere from $4-30M, with $11M being the median initial check size. The firm invests in both seed and crossover rounds. While most of the current portfolio companies are USA-based, the firm has a global portfolio and is open to global investment opportunities.
The firm focuses on these 3 key areas: therapeutics, diagnostics, and R&D tools/services. The firm also considers digital health opportunities that tie in with their key areas, such as technologies enhancing R&D efficacy, drug development process, etc. The firm stirs away from medical devices (basically, all technologies that require FDA approval), including implantable devices. With regards to the firm’s main interest areas, The firm is most interested in seeing new approaches (i.e. cell & gene therapy, novel ways of manufacturing cell lines, etc). The firm will invest in both pre-clinical and clinical technologies.
The firm has no specific company or management team requirements and is open to working with management teams coming from varying levels of experience. The firm prefers to act as the lead investor, and has done so for almost all of their portfolio companies thus far. The firm is a very active, hands-on investor and will generally seek board representation.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply